Noom is marketing its GLP-1 microdoses as a more cost-effective way to lose weight with fewer side effects, which may affect GLP-1 drug adherence
Among participants who met criteria for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) at baseline, more than 80% in the 8mg and 12mg cohorts no longer met those criteria after treatment effectively resolving their fatty liver disease
Starting with a diabetes indication may bypass some of the stricter prior authorization requirements that weight management indications trigger
The retatrutide duration and half-life information helps you understand how blood levels respond to timing shifts
Intra-market variation, especially for such a financially and demographically diverse area, reveals trends likely impacting the entire U.S
More Research Questions As researchers map GLP-1 receptor distribution, they are also searching for unifying mechanisms that could explain the drugs systemic effects
